Invitation to presentation of the Interim Report Q2 2020, on July 16 at 3 pm CET
Uppsala, Sweden – July 8, 2020 – As previously communicated Orexo will announce the Interim Report for Q2 2020, on Thursday, July 16 at 8.00 am CET. The same day at 3.00 pm CET (one hour later than normal), analysts, investors and media are invited to attend an audiocast with a web presentation where Nikolaj Sørensen, CEO, and Joseph DeFeo, CFO, will present the report. After the presentation a Q&A will be held. Questions can also be sent in advance to firstname.lastname@example.org, no later than 11.00 am CET.
Please view the instructions below on how to participate.
Telefon nr: SE: +46 8 566 427 06 UK: +44 33 330 090 32 UK: 1 833 526 8347
Prior to the event the presentation material will be available on Orexo´s website.
For further information, please contact:
Orexo AB (publ.)
Lena Wange, IR & Communications Director
Tel: +46 (0)18 780 88 00
Develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercialize its lead product ZUBSOLV® for treatment of opioid use disorder. Total net sales for 2019 amounted to SEK 844,8 million and the number of employees was 127. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where research and development is also performed, is situated in Uppsala, Sweden.
For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.